Research progress of the studies on the roots of Peucedanum praeruptorum dunn (Peucedani radix)

Yuelin Song; Wanghui Jing; Ru Yan; Yitao Wang
January 2015
Pakistan Journal of Pharmaceutical Sciences;Jan2015, Vol. 28 Issue 1, p71
Academic Journal
As a commonly employed traditional Chinese medicine, Peucedani Radix (Qian-hu in Chinese), which consists of the dried roots of Peucedanum praeruptorum Dunn, has a long history of application for the treatment of cough with thick sputum and dyspnea, nonproductive cough and upper air-way infections in traditional medicinal practice. The current review aims to summarize the research progress on the botany, phytochemistry, chemical analysis, pharmacological assay, and pharmacokinetic profile of this famous herbal drug. All available information on this traditional medicine was obtained via electronic search (using ACS, PubMed, Web of Science, Google Scholar, Baidu Scholar, and CNKI). Phytochemical investigations revealed that angular-type pyranocoumarins (APs), mainly (±)-praeruptorin A (Pd-Ia), (+)-praeruptorin A, (±)-praeruptorin B, (+)-praeruptorin B (Pd-II) and (+)-praeruptorin E (Pd- III), were the main active components in Qian-hu, while some other types of ingredients were also identified from this herb. The crude extract and pure compounds from Peucedani Radix exhibited a wide spectrum of in vitro and in vivo pharmacological activities, including vasorelaxant, cardioprotective, hepatoprotective, anti-tumor and anti-platelet aggregative effects. Conversely to the well-defined chemical constituents and activities, the properties of absorption, pharmacokinetics, and metabolism were rarely characterized. However, further investigations are wistful for the development of new drugs and therapies for various diseases, especially cardiovascular disorders. Collectively, the present review on the phytochemistry, chemical analysis, pharmacological evaluation, and pharmacokinetic profile of Peucedani Radix will provide meaningful information for further studies and commercial exploitation of the herbal medicine.


Related Articles

  • CV Therapeutics reports positive results from cardiometabolic diseases trial.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p8 

    The article reports on the announcement by CV Therapeutics Inc., a biopharmaceutical company, concerning positive results from a cardiometabolic diseases trial. The study assessed the pharmacokinetics of oral CVT- 3619, a partial A1 adenosine receptor agonist in obese volunteers. It is...

  • Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Hackshaw, A.; Knight, A.; Barrett-Lee, P.; Leonard, R. // British Journal of Cancer;11/28/2005, Vol. 93 Issue 11, p1215 

    Surrogate markers may help predict the effects of first-line treatment on survival. This metaregression analysis examines the relationship between several surrogate markers and survival in women with advanced breast cancer after receiving first-line combination anthracycline chemotherapy...

  • Oxigene's CA4P combination therapy begins trials.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p11 

    Reports that Oxigene Inc. has initiated a combination trial of its Combretastatin A4 Prodrug and the iodine-labeled antibody A5B7 in patients with advanced colorectal cancer. Analysis of the safety profile of the combination therapy; Determination of the maximum drug tolerance; Combination of...

  • Tarceva fails to meet primary endpoint.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p15 

    Reports that Genentech Inc.'s lung cancer drug Tarceva has failed to meet primary endpoints in two first-line phase III studies in the United States. Genentech's development of the drug in collaboration with OSI Pharmaceuticals and Roche; Clinical trials of Tarceva in combination with standard...

  • Celgene presents statistically significant data for prostate cancer drug.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p21 

    Reports that Celgene Corp. has presented statistically significant information from the clinical trial of Thalomid in combination with chemotherapy in androgen-dependent prostate cancer. Prostate-specific antigen response; Drug toxicity; Maximum tolerated dose.

  • Ziopharm Phase II Sarcoma Trial Reaches Goal Early. Hollingsworth, Catherine // BioWorld Today;10/15/2009, Vol. 20 Issue 199, p1 

    The article reports that the randomized trial of the sarcoma drug by Ziopharm Oncology Inc. has achieved results earlier than expected. The goal is to show progression-free survival (PFS) difference between the two groups. In the phase II of the trial patients were given either Zymafos plus...

  • Oncolytics Raises $12.7M to Prep for Phase III Reolysin Program.  // BioWorld Today;11/19/2009, Vol. 20 Issue 224, p1 

    This article reports on the move of Oncolytics Biotech Inc. to raise 12.75 million U.S. dollars to help cover the cost of its Phase III trial of Reolysin in head and neck cancer. The financing caused a decline in the company's shares. The trial administered Reolysin intravenously with paclitaxel...

  • Gemtuzumab Ozogamicin: A Review of its Use in Acute Myeloid Leukaemia. Fenton, Caroline; Perry, Caroline M. // Drugs;2005, Vol. 65 Issue 16, p2405 

    Gemtuzumab ozogamicin (Mylotarg®) is a conjugate of a monoclonal antibody and calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid leukaemia (AML) and, after cell internalisation, releases a derivative of the cytotoxic calicheamicin component. In the US, it is...

  • Panitumumab: A Review of its Use in Metastatic Colorectal Cancer. Keating, Gillian M. // Drugs;2010, Vol. 70 Issue 8, p1059 

    Panitumumab (Vectibix®) is a recombinant, fully human, lgG2 anti-epidermal growth factor receptor (EGFR) monoclonal antibody. This article reviews the clinical efficacy of intravenous panitumumab in combination with chemotherapy in the first- and second-line treatment of metastatic colorectal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics